Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Contingent consideration liabilities by Quarter
Contingent consideration liabilities — Noncurrent fair value ($M) ($M)
Pfizer Contingent consideration liabilities: $2,163M in Q2 2026. That is the highest of the 13 quarters on record here.
Latest, Q2 2026
2,163
Period ended Jun 28, 2026
Change on a year earlier
–
History
13 quarters
Since Q4 2018
Sources
12
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Fair Value Measurements — Contingent Consideration.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contingent consideration liabilities — Noncurrent fair value ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 2,163 | – | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 1,946 | – | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,695 | +255.3% | Form 10-Q (filed 2026-08-04) ↗ |
| Q4 2024 | Dec 31, 2024 | 477 | -6.8% | Form 10-K (filed 2026-02-26) ↗ |
| Q4 2023 | Dec 31, 2023 | 512 | -15.1% | Form 10-K (filed 2025-02-27) ↗ |
| Q4 2022 | Dec 31, 2022 | 603 | +7.1% | Form 10-K (filed 2024-02-22) ↗ |
| Q4 2021 | Dec 31, 2021 | 563 | -0.5% | Form 10-K (filed 2023-02-23) ↗ |
| Q4 2020 | Dec 31, 2020 | 566 | +2.7% | Form 10-K (filed 2022-02-24) ↗ |
| Q3 2020 | Sep 27, 2020 | 576 | – | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 28, 2020 | 570 | – | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 29, 2020 | 544 | – | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 551 | -22.2% | Form 10-K (filed 2021-02-25) ↗ |
| Q4 2018 | Dec 31, 2018 | 708 | – | Form 10-K (filed 2020-02-27) ↗ |
Cite this data
StockData. (2026). Pfizer Contingent consideration liabilities ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/cc-liab-noncur
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.